Literature DB >> 32243615

LncRNA XLOC_003810 promotes T cell activation and inhibits PD-1/PD-L1 expression in patients with myasthenia gravis-related thymoma.

Bo Hu1, Li Niu2, Zheng Jiang1, Shenglin Xu1, Yong Hu1, Kun Cao1.   

Abstract

This study aimed to investigate the effect of long non-coding RNA XLOC_003810 on the activation of CD4+ T cells and expression of PD-1/PD-L1 in patients with myasthenia gravis-related thymoma (MG-T). Thymus specimens and thymic mononuclear cells were obtained from MG and MG-T patients or cardiac surgery patients undergoing thoracotomy who were selected as negative controls (NC). XLOC_003810 expression was examined using quantitative real-time PCR (qRT-PCR). Frequency of CD4+ T cells and proportion of CD4+ PD-1+ T cells and CD14+ PD-L1+ monocytes were quantified by flow cytometry. The release of inflammatory cytokines was measured by qRT-PCR and enzyme-linked immunosorbent assay. Compared with the NC group, expression of XLOC_003810, frequency of CD4+ T cells and the production of inflammatory cytokines were increased in patients with MG and MG-T. XLOC_003810 overexpression significantly increased the frequency of CD4+ T cells, facilitated the production of inflammatory cytokines and decreased the proportion of CD4+ PD-1+ T cells and CD14+ PD-L1+ monocytes in the thymic mononuclear cells. In contrast, XLOC_003810 knockdown exerted the opposite effect. Together, XLOC_003810 promotes T cell activation and inhibits PD-1/PD-L1 pathway in patients with MG-T.
© 2020 The Scandinavian Foundation for Immunology.

Entities:  

Keywords:  PD-1; PD-L1; T cell; XLOC_003810; myasthenia gravis; thymoma

Year:  2020        PMID: 32243615     DOI: 10.1111/sji.12886

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  8 in total

1.  Long non-coding RNA growth arrest specific 5 regulates the T helper 17/regulatory T balance by targeting miR-23a in myasthenia gravis.

Authors:  Yingying Xu; Yiqun Ouyang
Journal:  J Int Med Res       Date:  2022-06       Impact factor: 1.573

2.  LncRNA LINC00680 Acts as a Competing Endogenous RNA and Is Associated With the Severity of Myasthennia Gravis.

Authors:  Li Liu; Huixue Zhang; Xiaoyu Lu; Lifang Li; Tianfeng Wang; Shuang Li; Xu Wang; Si Xu; Lei Li; Qian Li; Tingting Yi; Tao Wu; Zhimin Chen; Hongyu Gao; Jianjian Wang; Lihua Wang
Journal:  Front Neurol       Date:  2022-06-21       Impact factor: 4.086

Review 3.  Long Non-Coding RNAs in the Cell Fate Determination of Neoplastic Thymic Epithelial Cells.

Authors:  Alessia Iaiza; Claudia Tito; Federica Ganci; Andrea Sacconi; Enzo Gallo; Silvia Masciarelli; Giulia Fontemaggi; Alessandro Fatica; Enrico Melis; Vincenzo Petrozza; Federico Venuta; Mirella Marino; Giovanni Blandino; Francesco Fazi
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

Review 4.  A Review on the Role of Non-Coding RNAs in the Pathogenesis of Myasthenia Gravis.

Authors:  Soudeh Ghafouri-Fard; Tahereh Azimi; Bashdar Mahmud Hussen; Mohammad Taheri; Reza Jalili Khoshnoud
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

5.  LncRNA and mRNA expression associated with myasthenia gravis in patients with thymoma.

Authors:  Ji Ke; Xin Du; Jian Cui; Lei Yu; Hui Li
Journal:  Thorac Cancer       Date:  2021-11-12       Impact factor: 3.500

Review 6.  The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy.

Authors:  Wenxiao Jiang; Shuya Pan; Xin Chen; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Mol Cancer       Date:  2021-09-08       Impact factor: 27.401

7.  Competitive endogenous RNA network and pathway-based analysis of LncRNA single-nucleotide polymorphism in myasthenia gravis.

Authors:  Tianfeng Wang; Si Xu; Huixue Zhang; Xiaoyu Lu; Shuang Li; Li Liu; Xiaotong Kong; Hongyu Gao; Xu Wang; Shangwei Ning; Jianjian Wang; Lihua Wang
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379

8.  Thymic epithelial tumors: examining the GTF2I mutation and developing a novel prognostic signature with LncRNA pairs to predict tumor recurrence.

Authors:  Wei Liu; Hao-Shuai Yang; Shao-Yi Zheng; Jian-Hao Weng; Hong-He Luo; Yi-Yan Lei; Yan-Fen Feng
Journal:  BMC Genomics       Date:  2022-09-16       Impact factor: 4.547

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.